ADIL biotech catalysts & pipeline

ADIAL PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

AT177 — IND submission

Q2 2027

We plan to file an IND for AT177 in the second quarter of 2027 and to initiate a Phase 1a SAD/MAD study followed by a Phase 1b proof-of-concept study in UC patients, with an initial proof-of-concept readout anticipated in the first half of 2028.

Source filing

AT177 — Initial data

H1 2028

As of the date of this Quarterly Report on Form10-Q, we have completed a GLP toxicology in rats evaluating AT177, received pre-IND feedback from the U.S. Food and Drug Administration (the "FDA"), and are advancing AT177 through IND-enabling studies, with an IND planned for the second quarter of 2027.

Source filing

Explore the free biotech catalyst calendar